The importance of early action

Early intervention in this cascade of events, by favoring the clearance of the amyloid protein prior to its organization into fibrils and thereby maintaining its solubility, could clearly change disease outcome. This "disease-modifying" preventative and therapeutic intervention would be an effective and innovative approach to arresting the development of amyloid-related diseases. This is where Neurochem's technology enters into action.

Neurochem's core technology platform resides largely in the ability to design and synthesize small organic molecules that mimic the sulfated GAG molecules. Capitalizing on the key role of GAGs in the processes of amyloid fibril formation and deposition, Neurochem has designed and patented small organic molecules (drug candidates) to compete with these sulfated GAGs preventing the formation of amyloid fibrils, and the binding of the fibrillogenic amyloid proteins to the cells. In so doing, the therapeutic molecules inhibit the fibrillogenesis process. The Company refers to these drug candidates as "GAG mimetics". The Company believes that this approach introduces a new class of drug candidates for many of the amyloid-related diseases known to this day, including Alzheimer's disease, AA Amyloidosis, hemorrhagic stroke due to cerebral amyloid angiopathy and others.

The GAG mimetic

Neurochem's GAGs compete with natural GAGs for the same binding sites on the amyloid proteins, preventing the association of natural GAGs with the protein.

By preventing natural GAGs from binding to the amyloid proteins, the GAG mimetics can prevent fibril formation.

Our site is best viewed with IE4+ at a resolution of 1024×768.
All contents copyright © 1998-2007 Neurochem Inc.
Terms, Conditions and Legal Notice.